• Pharm Intermediate 5-Aminolevulinic Acid, Hydrochloride Salt CAS NO 925-45-1
  • Pharm Intermediate 5-Aminolevulinic Acid, Hydrochloride Salt CAS NO 925-45-1
Pharm Intermediate 5-Aminolevulinic Acid, Hydrochloride Salt CAS NO 925-45-1
  • Wuhan Hengheda Pharm Co.,Ltd
  • China
  • Immediately after payment
  • 1000kg/month

Aminolevulinic acid (ALA) is synthesized in mitochondria from glycine and succinyl-CoA by ALA synthetase (ALAS). Inhibition of ALAD results in activation of ALAS which further results in ALA accumulation in blood, plasma, and urine, thereby making ALA also a critical biomarker of early biological effects of Pb (Saxena and Flora, 2004). Effect of lead on bone marrow is more precisely depicted by increased ALA in plasma or blood than in urine, although ALA-U has been a recommended biomarker of Pb exposure. However, it can be detected only when blood Pb levels exceed 35 μg/dL in adults and 25–75 μg/dL in children, rendering it incapable of detecting low-level toxicity. Increased circulating levels of ALA may also result in decreased GABA release, resulting in behavioral disorders

Pharm Intermediate 5-Aminolevulinic Acid, Hydrochloride Salt CAS NO 925-45-1

The metabolism of aminolevulinic acid (ALA) is the first step in the biochemical pathway resulting in heme synthesis. Aminolevulinic acid is not a photosensitizer, but rather a metabolic precursor of protoporphyrin IX (PpIX), which is a photosensitizer. The synthesis of ALA is normally tightly controlled by feedback inhibition of the enzyme, ALA synthetase, presumably by intracellular heme levels. ALA, when provided to the cell, bypasses this control point and results in the accumulation of PpIX, which is converted into heme by ferrochelatase through the addition of iron to the PpIX nucleus.


According to the presumed mechanism of action, photosensitization following application of aminolevulinic acid (ALA) topical solution occurs through the metabolic conversion of ALA to protoporphyrin IX (PpIX), which accumulates in the skin to which aminolevulinic acid has been applied. When exposed to light of appropriate wavelength and energy, the accumulated PpIX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light results in an excited state of the porphyrin molecule, and subsequent spin transfer from PpIX to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Photosensitization of actinic (solar) keratosis lesions using aminolevulinic acid, plus illumination with the BLU-UTM Blue Light Photodynamic Therapy Illuminator (BLU-U), is the basis for aminolevulinic acid photodynamic therapy (PDT).


FAQ
Do we have the test reports for our products provided by the independent third party?
Every batch of our product was tested by authorized independent third party, Analysis testing center, Shanghai branch, Chinese Academy of Science. We send goods to customers with test report and COA. Our products were also tested by American Analytical Chemistry Laboratories and Chromadex too....more
Get the latest price? We'll respond as soon as possible(within 12 hours)

Privacy policy

close left right